Drug
QLC5508 clinical trials
Also written QLC5508.
- studies test it
- 4
- open now
- 4
- in phase 3
- 3
- first study started
- 2026
Keep track of what changes. Save the QLC5508 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses QLC5508 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug InteractionRecruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07620041Written as QLC5508 (Investigational Product / Formulation T)
- A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung CancerNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07802821Written as QLC5508
- QLC5508 in Participants With Metastatic Prostate CancerNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07632690Written as QLC5508
- QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell CarcinomaRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07463573Written as QLC5508
Given in every arm · 2 — QLC5508 is usual care beside what is tested
- A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07198633Written as QLC5508
- A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07256782Written as QLC5508